<p>CalciMedica Inc.（纳斯达克代码：CALC - 获取免费报告）在周二的交易中下跌了 2.1%。该公司的股价最低曾达到 5.55 美元，最后交易价格为 5.73 美元。在午盘交易中，共交易了 44,801 股，较平均交易量 92,307 股下降了 51%。该股票此前收盘价为 5.85 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 CalciMedica 股票的 “卖出（d-）” 评级。一位研究分析师给予该股票买入评级，另一位则给予卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价格为 16.00 美元。</p>
<p><strong>查看我们关于 CalciMedica 的最新股票报告</strong></p>
<h2>CalciMedica 股票表现</h2>
<p>该公司的债务与股本比率为 1.39，速动比率为 4.04，流动比率为 4.03。该公司的市值为 8256 万美元，市盈率为-3.54，贝塔系数为 0.58。该公司的 50 日简单移动平均线为 4.12 美元，200 日简单移动平均线为 3.24 美元。</p>
<p>CalciMedica（纳斯达克代码：CALC - 获取免费报告）最近于 11 月 12 日发布了季度财报。该公司报告本季度每股收益（EPS）为-0.39 美元，超出市场共识预期的-0.41 美元，超出幅度为 0.02 美元。平均而言，卖方分析师预计 CalciMedica Inc.在当前财年将发布-2.21 美元的每股收益。</p>
<h2>CalciMedica 的机构交易</h2>
<p>大型投资者最近调整了对该股票的持有。Stonehage Fleming Financial Services Holdings Ltd 在第三季度购买了价值 165,000 美元的 CalciMedica 新头寸。Meritage Portfolio Management 在第三季度将其在 CalciMedica 的持股增加了 33.8%。Meritage Portfolio Management 目前拥有 61,539 股该公司的股票，价值 189,000 美元，此前在此期间又购买了 15,539 股。Sheets Smith Investment Management 在第三季度收购了价值约 157,000 美元的 CalciMedica 新股份。Cetera Investment Advisers 在第二季度将其在 CalciMedica 的股份增加了 33.1%。Cetera Investment Advisers 目前拥有 36,385 股该公司的股票，价值 58,000 美元，此前在此期间又购买了 9,045 股。最后，Sound View Wealth Advisors Group LLC 在第二季度收购了价值约 32,000 美元的 CalciMedica 新头寸。</p>
<h2>CalciMedica 公司简介</h2>
<p>（获取免费报告）</p>
<p>CalciMedica, Inc.（纳斯达克代码：CALC）是一家临床阶段的生物制药公司，专注于开发调节钙介导的炎症通路的疗法。公司总部位于伊利诺伊州北布鲁克，应用专有的离子通道技术来应对由免疫反应失调引起的严重炎症疾病。</p>
<p>该公司的主要产品候选药物 Auxora™是一种选择性钙释放激活钙（CRAC）通道抑制剂。Auxora 正在临床试验中评估用于治疗与全身性炎症反应综合症（SIRS）和急性呼吸窘迫综合症（ARDS）相关的急性胰腺炎，适用于包括 COVID-19 肺炎在内的严重肺部疾病患者。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 CalciMedica 更好</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人只是看不见而已）</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
</ul>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 CalciMedica 吗？</h2>
<p>在你考虑投资 CalciMedica 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CalciMedica 并不在名单上。</p>
<p>虽然 CalciMedica 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CALC

<p>CalciMedica（纳斯达克代码：CALC）股价下跌 2.1%，至 5.73 美元，交易量较平均水平下降 51%。分析师的评级不一，给出了一项买入和一项卖出，导致共识评级为持有，目标价为 16.00 美元。该公司报告的季度每股收益为-0.39 美元，超出预期。机构投资者增加了持股比例，CalciMedica 专注于炎症性疾病的治疗。尽管评级为持有，分析师建议其他股票可能是更好的投资选择</p>

<p>CalciMedica Inc. (NASDAQ:CALC - Get Free Report) traded down 2.1% during trading on Tuesday . The company traded as low as $5.55 and last traded at $5.73. 44,801 shares were traded during mid-day trading, a decline of 51% from the average session volume of 92,307 shares. The stock had previously closed at $5.85.</p>
<div class="lb-trans"><p>CalciMedica Inc.（纳斯达克代码：CALC - 获取免费报告）在周二的交易中下跌了 2.1%。该公司的股价最低曾达到 5.55 美元，最后交易价格为 5.73 美元。在午盘交易中，共交易了 44,801 股，较平均交易量 92,307 股下降了 51%。该股票此前收盘价为 5.85 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of CalciMedica in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $16.00.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 CalciMedica 股票的 “卖出（d-）” 评级。一位研究分析师给予该股票买入评级，另一位则给予卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价格为 16.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on CalciMedica</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CalciMedica 的最新股票报告</strong></p>
</div><h2>CalciMedica Stock Performance</h2>
<div class="lb-trans"><h2>CalciMedica 股票表现</h2>
</div><p>The company has a debt-to-equity ratio of 1.39, a quick ratio of 4.04 and a current ratio of 4.03. The company has a market capitalization of $82.56 million, a price-to-earnings ratio of -3.54 and a beta of 0.58. The firm has a 50-day simple moving average of $4.12 and a two-hundred day simple moving average of $3.24.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 1.39，速动比率为 4.04，流动比率为 4.03。该公司的市值为 8256 万美元，市盈率为-3.54，贝塔系数为 0.58。该公司的 50 日简单移动平均线为 4.12 美元，200 日简单移动平均线为 3.24 美元。</p>
</div><p>CalciMedica (NASDAQ:CALC - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.02. On average, sell-side analysts anticipate that CalciMedica Inc. will post -2.21 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CalciMedica（纳斯达克代码：CALC - 获取免费报告）最近于 11 月 12 日发布了季度财报。该公司报告本季度每股收益（EPS）为-0.39 美元，超出市场共识预期的-0.41 美元，超出幅度为 0.02 美元。平均而言，卖方分析师预计 CalciMedica Inc.在当前财年将发布-2.21 美元的每股收益。</p>
</div><h2>Institutional Trading of CalciMedica</h2>
<div class="lb-trans"><h2>CalciMedica 的机构交易</h2>
</div><p>Large investors have recently modified their holdings of the stock. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in CalciMedica in the third quarter valued at $165,000. Meritage Portfolio Management increased its holdings in CalciMedica by 33.8% during the 3rd quarter. Meritage Portfolio Management now owns 61,539 shares of the company's stock worth $189,000 after purchasing an additional 15,539 shares during the period. Sheets Smith Investment Management acquired a new stake in CalciMedica in the 3rd quarter valued at about $157,000. Cetera Investment Advisers boosted its stake in shares of CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company's stock valued at $58,000 after buying an additional 9,045 shares during the period. Finally, Sound View Wealth Advisors Group LLC acquired a new position in shares of CalciMedica during the second quarter worth about $32,000.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该股票的持有。Stonehage Fleming Financial Services Holdings Ltd 在第三季度购买了价值 165,000 美元的 CalciMedica 新头寸。Meritage Portfolio Management 在第三季度将其在 CalciMedica 的持股增加了 33.8%。Meritage Portfolio Management 目前拥有 61,539 股该公司的股票，价值 189,000 美元，此前在此期间又购买了 15,539 股。Sheets Smith Investment Management 在第三季度收购了价值约 157,000 美元的 CalciMedica 新股份。Cetera Investment Advisers 在第二季度将其在 CalciMedica 的股份增加了 33.1%。Cetera Investment Advisers 目前拥有 36,385 股该公司的股票，价值 58,000 美元，此前在此期间又购买了 9,045 股。最后，Sound View Wealth Advisors Group LLC 在第二季度收购了价值约 32,000 美元的 CalciMedica 新头寸。</p>
</div><h2>CalciMedica Company Profile</h2>
<div class="lb-trans"><h2>CalciMedica 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CalciMedica, Inc NASDAQ: CALC is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.</p>
<div class="lb-trans"><p>CalciMedica, Inc.（纳斯达克代码：CALC）是一家临床阶段的生物制药公司，专注于开发调节钙介导的炎症通路的疗法。公司总部位于伊利诺伊州北布鲁克，应用专有的离子通道技术来应对由免疫反应失调引起的严重炎症疾病。</p>
</div><p>The company's lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 Auxora™是一种选择性钙释放激活钙（CRAC）通道抑制剂。Auxora 正在临床试验中评估用于治疗与全身性炎症反应综合症（SIRS）和急性呼吸窘迫综合症（ARDS）相关的急性胰腺炎，适用于包括 COVID-19 肺炎在内的严重肺部疾病患者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than CalciMedica</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 CalciMedica 更好</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人只是看不见而已）</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CalciMedica Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CalciMedica 吗？</h2>
</div><p>Before you consider CalciMedica, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 CalciMedica 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CalciMedica wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CalciMedica 并不在名单上。</p>
</div><p>While CalciMedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CalciMedica 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

CalciMedica (NASDAQ:CALC) 股价下跌 2.1% - 现在是卖出的时候吗？